After Daiichi (DSNKY) presented initial Phase 1 data from HR+/HER2- BC cohort for Trop2-ADC competitor Dato-DXd at SABCS, Piper Sandler analyst Do Kim said the data "were similar to possibly better than prior Trodelvy results," but added that Gilead’s (GILD) Trodelvy remains two years ahead of Dato-DXd in that indication. Kim, who expects Trodelvy to maintain its BC lead by eventual expansion into earlier lines, has an Overweight rating and $96 price target on Gilead shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Arcellx Soars on Key Deal with Gilead’s Kite
- ImmunoGen Joins hands with Gilead on AML Therapy
- Gilead’s Kite Pharma, Daiichi Sankyo announce partnership revision
- Kite, Daiichi Sankyo announces changes to Yescarta licensing deal in Japan
- Cantor biotech/biopharma analysts hold an analyst/industry conference call